Featured Research

from universities, journals, and other organizations

New agent to manage cancer related effusions

Date:
February 3, 2010
Source:
Wiley - Blackwell
Summary:
In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion -- development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and many patients suffer from significant breathlessness and distress. One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion. The current strategy is to induce a pleurodesis (seal the pleural cavity with a chemical agent so no fluid can accumulate). However existing agents are far from perfect, with most producing significant side effects while delivering low success rates.

In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion -- development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and many patients suffer from significant breathlessness and distress. One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion. The current strategy is to induce a pleurodesis (seal the pleural cavity with a chemical agent so no fluid can accumulate). However existing agents are far from perfect, with most producing significant side effects while delivering low success rates.

A recent issue of Respirology published by Wiley-Blackwell features two papers that propose the use of a new alternative pleurodesing agent, Iodoprovidone. They evaluate iodopovidone as a pleurodesis agent and found that it demonstrated good efficiency and safety, making it a good option in the management of malignant pleural effusion.

"There is not only a need to identify ideal pleurodesis agents, but also to standardize and optimize research tools to evaluate pleurodesis success in malignant effusions. In combination, these papers are complementary and warrant a critical appraisal of the current state of clinical research in malignant pleural effusion," said Andreas H. Diacon in an editorial published in the same issue of Respirology.

Pleurodesis is widely used to manage pleural diseases, such as malignant pleural effusion, by promoting pleural obliteration and preventing accumulation of air or fluid in the pleural space. This process would ideally alleviate shortness of breath, cough and pain associated with the presence of tumor and fluid in the pleural space.

In the paper, "Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits," researchers used a rabbit model to compare the effectiveness of iodopovidone in causing pleurodesis with that of doxycycline.

The study found that iodopovidone can induce pleurodesis as efficaciously as doxycycline and demonstrated that the desired outcome of pleurodesis can be achieved without prohibitive toxicity with a range of doses applicable to humans.

The other paper "Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions" is a retrospective analysis of iodopovidone pleurodesis in patients with malignant pleural effusions treated in a tertiary cancer institution.

Lead author Jose D.A. Neto said, "Out of the 61 pleurodesis procedures performed, no mortality was observed and less than 20 per cent presented complications. With the success rate of about 99 percent, iodopovidone appears to be a good option for the recurrent malignant pleural effusion."


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Journal References:

  1. Guo et al. Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits. Respirology, 2010; 15 (1): 119 DOI: 10.1111/j.1440-1843.2009.01671.x
  2. Neto et al. Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology, 2010; 15 (1): 115 DOI: 10.1111/j.1440-1843.2009.01663.x

Cite This Page:

Wiley - Blackwell. "New agent to manage cancer related effusions." ScienceDaily. ScienceDaily, 3 February 2010. <www.sciencedaily.com/releases/2010/02/100203084256.htm>.
Wiley - Blackwell. (2010, February 3). New agent to manage cancer related effusions. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/02/100203084256.htm
Wiley - Blackwell. "New agent to manage cancer related effusions." ScienceDaily. www.sciencedaily.com/releases/2010/02/100203084256.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins